Background
Janssen-Cilag has informed NICE that they "…understand from the clinical community that there is no desire to use ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukaemia (R/R CLL). Ibrutinib will only be used as monotherapy for the treatment of R/R CLL". As such, Janssen-Cilag will not be making an evidence submission to NICE for this indication.
NICE has therefore terminated this single technology appraisal.